全文获取类型
收费全文 | 314353篇 |
免费 | 26621篇 |
国内免费 | 10637篇 |
专业分类
耳鼻咽喉 | 2312篇 |
儿科学 | 6817篇 |
妇产科学 | 6127篇 |
基础医学 | 39377篇 |
口腔科学 | 6549篇 |
临床医学 | 25597篇 |
内科学 | 44596篇 |
皮肤病学 | 4297篇 |
神经病学 | 21743篇 |
特种医学 | 9606篇 |
外国民族医学 | 44篇 |
外科学 | 26991篇 |
综合类 | 47683篇 |
现状与发展 | 44篇 |
一般理论 | 8篇 |
预防医学 | 24024篇 |
眼科学 | 6589篇 |
药学 | 38121篇 |
96篇 | |
中国医学 | 17911篇 |
肿瘤学 | 23079篇 |
出版年
2024年 | 275篇 |
2023年 | 3780篇 |
2022年 | 5824篇 |
2021年 | 11293篇 |
2020年 | 10375篇 |
2019年 | 10055篇 |
2018年 | 10026篇 |
2017年 | 11132篇 |
2016年 | 11465篇 |
2015年 | 11249篇 |
2014年 | 15681篇 |
2013年 | 21059篇 |
2012年 | 17499篇 |
2011年 | 20367篇 |
2010年 | 14856篇 |
2009年 | 14773篇 |
2008年 | 16415篇 |
2007年 | 17427篇 |
2006年 | 16187篇 |
2005年 | 14740篇 |
2004年 | 12657篇 |
2003年 | 11172篇 |
2002年 | 8970篇 |
2001年 | 7985篇 |
2000年 | 6767篇 |
1999年 | 5588篇 |
1998年 | 4287篇 |
1997年 | 4130篇 |
1996年 | 3808篇 |
1995年 | 3617篇 |
1994年 | 3343篇 |
1993年 | 2734篇 |
1992年 | 2507篇 |
1991年 | 2277篇 |
1990年 | 1988篇 |
1989年 | 1609篇 |
1988年 | 1437篇 |
1987年 | 1307篇 |
1986年 | 1183篇 |
1985年 | 1696篇 |
1984年 | 1376篇 |
1983年 | 1003篇 |
1982年 | 1113篇 |
1981年 | 892篇 |
1980年 | 813篇 |
1979年 | 626篇 |
1978年 | 427篇 |
1977年 | 358篇 |
1976年 | 331篇 |
1975年 | 252篇 |
排序方式: 共有10000条查询结果,搜索用时 140 毫秒
21.
22.
Major depressive disorder and other neuropsychiatric disorders are often managed with long-term use of antidepressant medication. Fluoxetine, an SSRI antidepressant, is widely used as a first-line treatment for neuropsychiatric disorders. However, fluoxetine has also been shown to increase the risk of metabolic diseases such as non-alcoholic fatty liver disease. Fluoxetine has been shown to increase hepatic lipid accumulation in vivo and in vitro. In addition, fluoxetine has been shown to alter the production of prostaglandins which have also been implicated in the development of non-alcoholic fatty liver disease. The goal of this study was to assess the effect of fluoxetine exposure on the prostaglandin biosynthetic pathway and lipid accumulation in a hepatic cell line (H4-II-E-C3 cells). Fluoxetine treatment increased mRNA expression of prostaglandin biosynthetic enzymes (Ptgs1, Ptgs2, and Ptgds), PPAR gamma (Pparg), and PPAR gamma downstream targets involved in fatty acid uptake (Cd36, Fatp2, and Fatp5) as well as production of 15-deoxy-Δ12,14PGJ2 a PPAR gamma ligand. The effects of fluoxetine to induce lipid accumulation were attenuated with a PTGS1 specific inhibitor (SC-560), whereas inhibition of PTGS2 had no effect. Moreover, SC-560 attenuated 15-deoxy-Δ12,14PGJ2 production and expression of PPAR gamma downstream target genes. Taken together these results suggest that fluoxetine-induced lipid abnormalities appear to be mediated via PTGS1 and its downstream product 15d-PGJ2 and suggest a novel therapeutic target to prevent some of the adverse effects of fluoxetine treatment. 相似文献
23.
卫逸涛肖惠敏谢银环孙丽军 《中华健康管理学杂志》2022,(8):547-552
目的了解老年人生命晚期获知疾病相关信息意向及影响因素。方法2016年10月至2017年6月,采用生命晚期疾病信息意向问卷,利用方便抽样法对福州市中心城区7所养老机构及15个社区的414例年龄≥60岁的老年人进行横断面调查,采用单因素分析、多元线性回归与有序多分类logistic回归分析老年人对疾病相关信息的需求水平、获知程度意向及其影响因素。结果414例老年人疾病相关信息需求得分为(17.1±4.9)分;48.8%(202/414)希望详尽知晓,30.7%(127/414)希望选择性了解,20.5%(85/414)不想知道任何信息;多元线性回归分析显示,年龄、文化程度、是否接受/见过其他生命维持治疗(LSTs)是影响老年人疾病相关信息需求水平的主要因素(标准化回归系数分别为-0.141、0.116、0.115,均P<0.05);有序多分类logistic分析显示,年龄(以60~69岁为参照,70~79岁:OR=0.544,95%CI:0.310~0.957;80~89岁:OR=0.526,95%CI:0.289~0.956)、文化程度(以小学及以下为参照,大专及以上:OR=2.166,95%CI:1.093~4.290)、主要生活费来源(以其他补贴为参照,家人支持:OR=7.303,95%CI:1.157~46.108;退休金:OR=9.288,95%CI:1.502~57.415;公积金/储蓄:OR=15.676,95%CI:2.122~115.793)、是否接受/见过其他LSTs(以是为参照,OR=1.985,95%CI:1.150~3.425)是影响老年人疾病相关信息获知程度意向的主要因素。结论老年人生命晚期获知疾病相关信息的意向程度较高,年龄、文化程度、主要生活费来源、是否接受/见过其他生命维持治疗等是其主要影响因素。 相似文献
24.
25.
26.
目的:运用新型光学生物测量仪IOL Master 700测量白内障超声乳化手术前后眼部生物学参数的变化,并探讨人工晶状体(IOL)屈光度数计算公式的选择。
方法:前瞻性研究。收集2021-01/06在苏州大学附属第一医院就诊的白内障患者52例57眼。术前和术后3mo使用IOL Master 700完成眼轴长度(AL)、前房深度(ACD)、角膜曲率(Km)的测量并分析。对不同IOL公式计算时预留的目标屈光值与术后3mo全自动验光仪实际屈光值结果进行比较并分析。
结果:手术前后测量的AL平均值分别为24.20±1.86、24.09±1.86mm,术后AL缩短了0.11mm; ACD值分别为3.08±0.44、4.55±0.36mm(P<0.001),术后ACD加深1.49mm; Km值分别为44.14±1.86、44.14±1.82D(P>0.05)。术前选用Barrett Universal Ⅱ公式所测结果的屈光误差最小,其次是Holladay Ⅱ及SRK/T公式,Holladay Ⅰ公式所测结果的误差最大(P<0.05)。
结论:白内障术后AL缩短以及ACD加深,度数测算时可考虑增加0.1mm的校正因子。IOL屈光度数计算公式中Barrett Universal Ⅱ公式预测性最佳,其次是Holladay Ⅱ及SRK/T公式。 相似文献
27.
《Journal of vascular and interventional radiology : JVIR》2022,33(10):1213-1221.e5
PurposeTo investigate the pharmacokinetics (PK) and early effects of conventional transarterial chemoembolization (TACE) using sorafenib and doxorubicin on tumor necrosis, hypoxia markers, and angiogenesis in a rabbit VX2 liver tumor model.Materials and MethodsVX2 tumor-laden New Zealand White rabbits (N = 16) were divided into 2 groups: 1 group was treated with hepatic arterial administration of ethiodized oil and doxorubicin emulsion (DOX-TACE), and the other group was treated with ethiodized oil, sorafenib, and doxorubicin emulsion (SORA-DOX-TACE). Animals were killed within 3 days of the procedure. Levels of sorafenib and doxorubicin were measured in blood, tumor, and adjacent liver using mass spectrometry. Tumor necrosis was determined by histopathological examination. Intratumoral hypoxia-inducible factor (HIF) 1α, vascular endothelial growth factor (VEGF), and microvessel density (MVD) were determined by immunohistochemistry.ResultsThe median intratumoral concentration of sorafenib in the SORA-DOX-TACE group was 17.7 μg/mL (interquartile range [IQR], 7.42–33.5 μg/mL), and its maximal plasma concentration (Cmax) was 0.164 μg/mL (IQR, 0.0798–0.528 μg/mL). The intratumoral concentration and Cmax of doxorubicin were similar between the groups: 4.08 μg/mL (IQR, 3.18–4.79 μg/mL) and 0.677 μg/mL (IQR, 0.315–1.23 μg/mL), respectively, in the DOX-TACE group and 1.68 μg/mL (IQR, 0.795–4.08 μg/mL) and 0.298 μg/mL (IQR, 0.241–0.64 μg/mL), respectively, in the SORA-DOX-TACE group. HIF-1α expression was increased in the SORA-DOX-TACE group than in the DOX-TACE group. Tumor volume, tumor necrosis, VEGF expression, and MVD were similar between the 2 groups.ConclusionsThe addition of sorafenib to DOX-TACE delivered to VX2 liver tumors resulted in high intratumoral and low systemic concentrations of sorafenib without altering the PK of doxorubicin. 相似文献
28.
The objective of the present study was the development and validation of the method for determining AMB-FUBINACA and its metabolite - AMB-FUBINACA O-desmethyl acid – in blood samples, followed by verification of the method in toxicological judicial and forensic medicine practice employing the example of post-aggression suicide. Most likely in consequence of development of adverse effects resulting in psychotic symptoms, a male being under the influence of the synthetic cannabinoid AMB-FUBINACA and the new synthetic opioid U-47700, mortally wounded his female partner and subsequently committed suicide. Identification and determination of the afore-mentioned xenobiotics in blood samples collected from the male and female victims were performed employing high performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (HPLC-ESI-MS/MS). The analytes were isolated from blood samples using the solid phase extraction (SPE) method. The blood samples collected from the male and female demonstrated respectively 110 and 196 ng/mL of AMB-FUBINACA O-desmethyl acid metabolite, 1935 and 357 ng/mL of U-47700, 250 and 200 ng/mL of N-desmethyl-U-47700, as well as 410 and 200 ng/mL of N,N-didesmethyl-U-47700. The concentration values of new psychoactive substances (NPS’s) in blood samples originating from the male and female were within the ranges encountered in cases of poisoning, including these resulting in death. Nevertheless, the evident signs of exsanguination proof that the woman was alive when she sustained lethal injuries. The presented cases illustrate the difficult to be anticipated effect exerted on the users by NPS’s. 相似文献
29.
30.
Laura A. Huppert MD Ozge Gumusay MD Dame Idossa MD Hope S. Rugo MD 《CA: a cancer journal for clinicians》2023,73(5):480-515
Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer is defined by the presence of the estrogen receptor and/or the progesterone receptor and the absence of HER2 gene amplification. HR-positive/HER2-negative breast cancer accounts for 65%–70% of all breast cancers, and incidence increases with increasing age. Treatment varies by stage, and endocrine therapy is the mainstay of treatment in both early stage and late-stage disease. Combinations with cyclin-dependent kinase 4/6 inhibitors have reduced distant recurrence in the early stage setting and improved overall survival in the metastatic setting. Chemotherapy is used based on stage and tumor biology in the early stage setting and after endocrine resistance for advanced disease. New therapies, including novel endocrine agents and antibody-drug conjugates, are now changing the treatment landscape. With the availability of new treatment options, it is important to define the optimal sequence of treatment to maximize clinical benefit while minimizing toxicity. In this review, the authors first discuss the pathologic and molecular features of HR-positive/HER2-negative breast cancer and mechanisms of endocrine resistance. Then, they discuss current and emerging therapies for both early stage and metastatic HR-positive/HER2-negative breast cancer, including treatment algorithms based on current data. 相似文献